Replies to post #110396 on Biotech Values

[DewDiligence]

BMY/ABBV report phase-2 PFS data for Elotuzumab in second-line MM:

http://finance.yahoo.com/news/elotuzumab-progression-free-survival-data-213000322.html

Prior results from this study—including ORR, the primary endpoint—were reported at ASH 2010 (#msg-57504180).